S Chiloiro1, M Mormando1, A Bianchi1, A Giampietro1, D Milardi1, C Bima1, G Grande1, A M Formenti2, G Mazziotti3, A Pontecorvi1, A Giustina4, L De Marinis5. 1. Department of Endocrinology, Catholic University of the Sacred Heart, Rome, Italy. 2. Department of Molecolar and Translational Medicine, University of Brescia, Brescia, Italy. 3. Department of Medicine, Endocrine and Bone Unit, ASST Carlo Poma, Mantua, Italy. 4. Chair of Endocrinology, Vita-Salute San Raffaele University, Milan, Italy. 5. Department of Endocrinology, Catholic University of the Sacred Heart, Rome, Italy. laurademarinis@yahoo.it.
Abstract
INTRODUCTION: Skeletal fragility with high risk of vertebral fractures is an emerging complication of acromegaly in close relationship with duration of active disease. The aim of this cross-sectional study was to evaluate the prevalence and determinants of vertebral fractures in males and females with a history of long-standing active acromegaly undergoing treatment with Pegvisomant. SUBJECTS AND METHODS: Thirty-eight patients (25 females, 13 males) with acromegaly under Pegvisomant therapy were evaluated for vertebral fractures and bone mineral density at lumbar spine and femoral neck. Gonadal status, serum IGF1 levels and growth hormone receptor genotype were also assessed. RESULTS: Vertebral fractures were detected in 12 patients (31.6%). Fractured patients had longer duration of active disease (p = 0.01) with higher frequency of active acromegaly (p = 0.04), received higher dose of Pegvisomant (p = 0.008), and were more frequently hypogonadic (p = 0.02) as compared to patients who did not fracture. Stratifying the patients for gender, vertebral fractures were significantly associated with Pegvisomant dose (p = 0.02) and untreated hypogonadism (p = 0.02) in males and with activity of disease (p = 0.03), serum insulin-like growth factor-I values (p = 0.01) and d3GHR polymorphism (p = 0.005) in females. No significant association was found between vertebral fractures and bone mineral density at either skeletal site. CONCLUSION: Vertebral fractures are a frequent complication of long-standing active acromegaly. When patients are treated with Pegvisomant, vertebral fractures may occur in close relationship with active acromegaly and coexistent untreated hypogonadism.
INTRODUCTION: Skeletal fragility with high risk of vertebral fractures is an emerging complication of acromegaly in close relationship with duration of active disease. The aim of this cross-sectional study was to evaluate the prevalence and determinants of vertebral fractures in males and females with a history of long-standing active acromegaly undergoing treatment with Pegvisomant. SUBJECTS AND METHODS: Thirty-eight patients (25 females, 13 males) with acromegaly under Pegvisomant therapy were evaluated for vertebral fractures and bone mineral density at lumbar spine and femoral neck. Gonadal status, serum IGF1 levels and growth hormone receptor genotype were also assessed. RESULTS:Vertebral fractures were detected in 12 patients (31.6%). Fracturedpatients had longer duration of active disease (p = 0.01) with higher frequency of active acromegaly (p = 0.04), received higher dose of Pegvisomant (p = 0.008), and were more frequently hypogonadic (p = 0.02) as compared to patients who did not fracture. Stratifying the patients for gender, vertebral fractures were significantly associated with Pegvisomant dose (p = 0.02) and untreated hypogonadism (p = 0.02) in males and with activity of disease (p = 0.03), serum insulin-like growth factor-I values (p = 0.01) and d3GHR polymorphism (p = 0.005) in females. No significant association was found between vertebral fractures and bone mineral density at either skeletal site. CONCLUSION:Vertebral fractures are a frequent complication of long-standing active acromegaly. When patients are treated with Pegvisomant, vertebral fractures may occur in close relationship with active acromegaly and coexistent untreated hypogonadism.
Authors: Hugo R Boquete; Patricia G V Sobrado; Hugo L Fideleff; Ana M Sequera; Ana V Giaccio; Martha G Suárez; Gabriela F Ruibal; Mirta Miras Journal: J Clin Endocrinol Metab Date: 2003-10 Impact factor: 5.958
Authors: Antonio Bianchi; Gherardo Mazziotti; Laura Tilaro; Vincenzo Cimino; Flora Veltri; Eleonora Gaetani; Giovanni Pecorini; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis Journal: Pituitary Date: 2009 Impact factor: 4.107
Authors: A Giustina; G Arnaldi; F Bogazzi; S Cannavò; A Colao; L De Marinis; E De Menis; E Degli Uberti; F Giorgino; S Grottoli; A G Lania; P Maffei; R Pivonello; E Ghigo Journal: J Endocrinol Invest Date: 2017-02-07 Impact factor: 4.256
Authors: J Pontes; M Madeira; C H A Lima; L L Ogino; F de Paula Paranhos Neto; L M C de Mendonça; M L F Farias; L Kasuki; M R Gadelha Journal: J Endocrinol Invest Date: 2019-08-07 Impact factor: 4.256
Authors: Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli Journal: Endocrine Date: 2020-02-14 Impact factor: 3.633
Authors: Renato Cozzi; Maria R Ambrosio; Roberto Attanasio; Alessandro Bozzao; Laura De Marinis; Ernesto De Menis; Edoardo Guastamacchia; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Pietro Maffei; Maurizio Poggi; Vincenzo Toscano; Michele Zini; Philippe Chanson; Laurence Katznelson Journal: Endocr Metab Immune Disord Drug Targets Date: 2020 Impact factor: 2.895
Authors: Lukas Andereggen; Janine Frey; Robert H Andres; Markus M Luedi; Hans Rudolf Widmer; Jürgen Beck; Luigi Mariani; Emanuel Christ Journal: Sci Rep Date: 2021-03-04 Impact factor: 4.379
Authors: Sabrina Chiloiro; Antonella Giampietro; Irene Gagliardi; Marta Bondanelli; Miriam Veleno; Maria Rosaria Ambrosio; Maria Chiara Zatelli; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis; Antonio Bianchi Journal: Pituitary Date: 2022-08-03 Impact factor: 3.599